Applied DNA Sciences Statistics
Share Statistics
Applied DNA Sciences has 51.22M shares outstanding. The number of shares has increased by -24.59% in one year.
| Shares Outstanding | 51.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 945.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 51.21M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 611.10K, so 1.21% of the outstanding shares have been sold short.
| Short Interest | 611.10K |
| Short % of Shares Out | 1.21% |
| Short % of Float | 1.21% |
| Short Ratio (days to cover) | 0.12 |
Valuation Ratios
The PE ratio is -1.59 and the forward PE ratio is -0.18.
| PE Ratio | -1.59 |
| Forward PE | -0.18 |
| PS Ratio | 1.18 |
| Forward PS | 1.6 |
| PB Ratio | 3.2 |
| P/FCF Ratio | -2.51 |
| PEG Ratio | n/a |
Enterprise Valuation
Applied DNA Sciences Inc. has an Enterprise Value (EV) of 310.51M.
| EV / Earnings | -31.22 |
| EV / Sales | 23.23 |
| EV / EBITDA | -32.38 |
| EV / EBIT | -28.35 |
| EV / FCF | -49.32 |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of 0.
| Current Ratio | 2.86 |
| Quick Ratio | 2.74 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.01% and return on capital (ROIC) is -179.26%.
| Return on Equity (ROE) | -2.01% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -179.26% |
| Revenue Per Employee | 257.07K |
| Profits Per Employee | -191.29K |
| Employee Count | 52 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 23.74 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -98.71% in the last 52 weeks. The beta is 0.45, so Applied DNA Sciences 's price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -98.71% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 51.69 |
| Average Volume (20 Days) | 4.49M |
Income Statement
In the last 12 months, Applied DNA Sciences had revenue of $13.37M and earned -$9.95M in profits. Earnings per share was $-15.21.
| Revenue | 13.37M |
| Gross Profit | 5.53M |
| Operating Income | -10.95M |
| Net Income | -9.95M |
| EBITDA | -9.59M |
| EBIT | -10.95M |
| Earnings Per Share (EPS) | -15.21 |
Balance Sheet
The company has $7.15M in cash and $1.24M in debt, giving a net cash position of $5.91M.
| Cash & Cash Equivalents | 7.15M |
| Total Debt | 1.24M |
| Net Cash | 5.91M |
| Retained Earnings | -302.45M |
| Total Assets | 16.69M |
| Working Capital | 8.82M |
Cash Flow
In the last 12 months, operating cash flow was -$6.22M and capital expenditures -$78.45K, giving a free cash flow of -$6.30M.
| Operating Cash Flow | -6.22M |
| Capital Expenditures | -78.45K |
| Free Cash Flow | -6.30M |
| FCF Per Share | -9.63 |
Margins
Gross margin is 41.39%, with operating and profit margins of -81.94% and -74.41%.
| Gross Margin | 41.39% |
| Operating Margin | -81.94% |
| Pretax Margin | -74.98% |
| Profit Margin | -74.41% |
| EBITDA Margin | -71.75% |
| EBIT Margin | -81.94% |
| FCF Margin | -47.1% |
Dividends & Yields
APDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9506.25% |
| FCF Yield | -77.65% |
Analyst Forecast
The average price target for APDN is $1.5, which is 837.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.5 |
| Price Target Difference | 837.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 25, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -26.27 |
| Piotroski F-Score | 1 |